Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (95)	1/26/1999 6:09:00 PM
From: Biomaven	Read Replies (3) \| Respond to of 3158

David, CHIR is half-eaten by Novartis already, so I can't see anyone else taking a bite <G>. We've speculated on this thread who CHIR itself might grab. The "prey" portfolio shows some of the munchees we have discussed on the thread, although a lot of these are third tier that the powers that be don't seem real interested in right now. If the other big pharma start playing copycat, then any of the second tier could be a target, particularly those that are not already tightly partnered up and would not be too dilutive. Even some of the first tier like Biogen could conceivably be targets, but they are pretty pricey already. We should see a good day for biotechs tomorrow. Peter